Bloomberg the Company

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Follow Us

Industry Products

  • Exchange: SIX Swiss Ex
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Large Pharma

NOVN:VX

91.000 CHF 2.300 2.59%

As of 11:31:18 ET on 01/29/2015.

Snapshot for Novartis AG (NOVN)

Open: 88.500 Day's Range: 88.450 - 91.000 Volume: 7,707,993
Previous Close: 88.700 52wk Range: 70.150 - 99.750 1-Yr Rtn: +31.46%

Stock Chart for NOVN

No chart data available.
  • NOVN:VX 90.800
  • 1D
  • 1M
  • 1Y
88.700
Interactive NOVN Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Close:
Open:
High:
Low:
Volume:
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for NOVN

Current P/E Ratio (ttm) 21.5802
Estimated P/E(12/2015) 18.0744
Relative P/E vs. SMI 1.1031
Earnings Per Share (USD) (ttm) 4.5537
Est. EPS (USD) (12/2015) 5.4410
Est. PEG Ratio 2.5732
Market Cap (M CHF) 243,827.99
Shares Outstanding (M) 2,706.19
30 Day Average Volume 8,339,914
Price/Book (mrq) 3.3266
Price/Sale (ttm) 4.4480
Dividend Indicated Gross Yield 2.89%
Cash Dividend (CHF) 2.6000
Dividend Ex-Date 03/03/2015
5 Year Dividend Growth 4.14%
Next Earnings Announcement 04/23/2015
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for NOVN

  • Revenue
  • Net Income (M/USD)
  • Profit Margin (%)

Company Profile & Key Executives for NOVN

Novartis AG manufactures pharmaceutical and consumer healthcare products. The Company produces pharmaceuticals for cardiovascular, respiratory and infectious diseases, oncology, neuroscience, transplantation, dermatology, gastrointestinal and urinary conditions, and arthritis, vaccines and diagnostics, vision, and animal health products.

Joseph Jimenez Jr "Joe"Chief Executive OfficerHarry KirschChief Financial Officer
Andre Wyss "Andy"President:SwitzerlandMark C FishmanPresident:Nibr
More Company Profile & Key Executives for NOVN

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Advertisement
Advertisement
Sponsored Links
Advertisements
sec ||= nil